

# Peng Wu, P Wu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2483868/publications.pdf>

Version: 2024-02-01

43  
papers

2,730  
citations

471061

17  
h-index

253896

43  
g-index

48  
all docs

48  
docs citations

48  
times ranked

4630  
citing authors

#	ARTICLE	IF	CITATIONS
1	FDA-approved small-molecule kinase inhibitors. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 422-439.	4.0	794
2	Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. <i>Drug Discovery Today</i> , 2016, 21, 5-10.	3.2	383
3	Reactivity and Synthetic Applications of Multicomponent Petasis Reactions. <i>Chemical Reviews</i> , 2019, 119, 11245-11290.	23.0	173
4	Allosteric small-molecule kinase inhibitors. , 2015, 156, 59-68.		166
5	Scaffold Diversity from <i>N</i> -Acyliminium Ions. <i>Chemical Reviews</i> , 2017, 117, 7811-7856.	23.0	155
6	A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9. <i>Cell</i> , 2019, 177, 1067-1079.e19.	13.5	133
7	Phosphorylation-Inducing Chimeric Small Molecules. <i>Journal of the American Chemical Society</i> , 2020, 142, 14052-14057.	6.6	90
8	PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress. <i>Current Medicinal Chemistry</i> , 2010, 17, 4326-4341.	1.2	89
9	Inhibition of RNA-binding proteins with small molecules. <i>Nature Reviews Chemistry</i> , 2020, 4, 441-458.	13.8	76
10	Searching for the Multi-Target-Directed Ligands against Alzheimer's disease: Discovery of quinoxaline-based hybrid compounds with AChE, H3R and BACE 1 inhibitory activities. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 7158-7167.	1.4	63
11	Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5610-5615.	1.4	56
12	Small molecules targeting phosphoinositide 3-kinases. <i>MedChemComm</i> , 2012, 3, 1337.	3.5	54
13	Clinical and Marketed Proteasome Inhibitors for Cancer Treatment. <i>Current Medicinal Chemistry</i> , 2013, 20, 2537-2551.	1.2	43
14	PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?. <i>Current Medicinal Chemistry</i> , 2009, 16, 916-930.	1.2	38
15	Synthesis, biological evaluation and quantitative structure-activities relationship of flavonoids as vasorelaxant agents. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 716-726.	1.4	33
16	Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl)quinoxalines as PI3K± inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 5540-5548.	2.6	31
17	Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 99, 36-50.	2.6	25
18	Trisubstituted Pyrrolinones as Small-Molecule Inhibitors Disrupting the Protein-RNA Interaction of LIN28 and Let-7. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 893-898.	1.3	22

#	ARTICLE	IF	CITATIONS
19	A microwave-assisted multicomponent synthesis of substituted 3,4-dihydroquinazolinones. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 2044-2054.	1.5	20
20	Optochemical Control of Protein Degradation. <i>ChemBioChem</i> , 2020, 21, 2250-2252.	1.3	17
21	Small molecules with tetrahydroquinoline-containing Povarov scaffolds as inhibitors disrupting the Protein-RNA interaction of LIN28let-7. <i>European Journal of Medicinal Chemistry</i> , 2022, 228, 114014.	2.6	17
22	Discovery of novel morpholino-quinoxalines as PI3K $\pm$ inhibitors by pharmacophore-based screening. <i>MedChemComm</i> , 2012, 3, 659.	3.5	16
23	Discovery of novel 2-piperidinol-3-(arylsulfonyl)quinoxalines as phosphoinositide 3-kinase $\pm$ (PI3K $\pm$ ) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2837-2844.	1.4	16
24	Synthesis of (Arylamido)pyrrolidinone Libraries through Ritter-Type Cascade Reactions of Dihydroxylactams. <i>European Journal of Organic Chemistry</i> , 2015, 2015, 5633-5639.	1.2	16
25	Synthesis of hexahydropyrrolo[2,1-a]isoquinoline compound libraries through a Pictet-Spengler cyclization/metal-catalyzed cross coupling/amidation sequence. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2646-2649.	1.4	16
26	Flavonoids as Vasorelaxant Agents: Synthesis, Biological Evaluation and Quantitative Structure Activities Relationship (QSAR) Studies. <i>Molecules</i> , 2011, 16, 8257-8272.	1.7	15
27	Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 5679-5687.	1.4	15
28	Synthesis of 1,4,5 trisubstituted $\hat{I}^3$ -lactams via a 3-component cascade reaction. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2695-2698.	1.4	15
29	Reductive Cyclization and Petasis-Like Reaction for the Synthesis of Functionalized $\hat{I}^3$ -Lactams. <i>European Journal of Organic Chemistry</i> , 2015, 2015, 2346-2350.	1.2	14
30	Petasis three-component reactions for the synthesis of diverse heterocyclic scaffolds. <i>Drug Discovery Today: Technologies</i> , 2018, 29, 27-33.	4.0	14
31	Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 866-881.	4.0	13
32	Multicomponent Petasis Reaction for the Synthesis of Functionalized 2-Aminothiophenes and Thienodiazepines. <i>ACS Combinatorial Science</i> , 2020, 22, 495-499.	3.8	12
33	Tandem Mannich/Diels-Alder reactions for the synthesis of indole compound libraries. <i>RSC Advances</i> , 2016, 6, 46654-46657.	1.7	11
34	A metal-catalyzed enyne-cyclization step for the synthesis of bi- and tricyclic scaffolds amenable to molecular library production. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 6947-6950.	1.5	11
35	Identification and Structure-Activity Relationship Study of Imidazo[1,2- <i>a</i> ]pyridine-3-amines as First Selective Inhibitors of Excitatory Amino Acid Transporter Subtype 3 (EAAT3). <i>ACS Chemical Neuroscience</i> , 2019, 10, 4414-4429.	1.7	11
36	Diastereoselective synthesis of novel heterocyclic scaffolds through tandem Petasis 3-component/intramolecular Diels-Alder and ROM-RCM reactions. <i>Chemical Communications</i> , 2017, 53, 9410-9413.	2.2	10

#	ARTICLE	IF	CITATIONS
37	Synthesis and evaluation of RNase L-binding 2-aminothiophenes as anticancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 58, 116653.	1.4	9
38	QSAR Models for isoindolinone-based p53-MDM2 Interaction Inhibitors Using Linear and Non-linear Statistical Methods. <i>Chemical Biology and Drug Design</i> , 2012, 79, 691-702.	1.5	8
39	Design, Synthesis, Biological Evaluation, and Docking Studies of <i>S</i> -Phenylalanine Derivatives with a 2-Cyanopyrrolidine Moiety as Potent Dipeptidyl Peptidase 4 Inhibitors. <i>Chemical Biology and Drug Design</i> , 2013, 82, 140-146.	1.5	7
40	Synthesis of Novel 1,4-Benzoxazine-2,3-Dicarboximides from Maleic Anhydride and Substituted Aromatic Amines. <i>Synthetic Communications</i> , 2008, 39, 70-84.	1.1	5
41	Design, synthesis and biological evaluation of 3-benzylidene flavanone derivatives as cytotoxic agents. <i>Medicinal Chemistry Research</i> , 2012, 21, 4150-4157.	1.1	5
42	Cyclobutane-containing scaffolds in bioactive small molecules. <i>Trends in Chemistry</i> , 2022, 4, 677-681.	4.4	5
43	Identification of Novel Piperazinylquinoxaline Derivatives as Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors. <i>PLoS ONE</i> , 2012, 7, e43171.	1.1	3